Caliper’s Revenues Shoot Up, but Losses Stay Flat in Q1
Caliper Life Sciences last week reported a three-fold revenue increase year-over-year for the first quarter of 2004, while losses remained stable. Revenues were $16.9 million, up from $5.6 million during the same period last year. This increase was mainly due to revenues from Zymark, which Caliper acquired last July.
R&D expenses decreased to $6.5 million, from $9.4 million during the same quarter in 2003.
Caliper’s net loss for the quarter was $10 million, or $.35 per share, compared to $10 million, or $.40 per share, during the year-ago period.
At the end of the quarter, Caliper had $5.6 million in cash and cash equivalents, and $50.3 million in marketable securities.
FASEB Urges Members to Reject Proposed FY 2005 US Budget
The Federation of American Societies for Experimental Biology sent an e-mail alert last week to its members urging them to oppose the FY 2005 budget resolutions passed by the two houses of the US Congress.
FASEB is composed of members of 22 scientific societies numbering over 65,000 US scientists.
US President George Bush’s budget proposal, which included a 2.6 percent increase for the NIH, already came under fire from the American Association for the Advancement of Science three weeks ago, and scientists have expressed their concern about future NIH budgets to ProteoMonitor (see PM 5-7-04). The budget proposed by the House of Representatives would provide $1.6 billion less than the President’s budget and the Senate’s would provide $2.3 billion less. A budget conference committee will attempt to resolve the differences between the House and Senate, but the resulting compromise is still expected to be lower than Bush’s budget, according to FASEB.
Bio-Rad’s Revenues Rise, Income Drops in Q1
Bio-Rad reported increased revenues but a drop in income for the first quarter of 2004 last week.
Bio-Rad’s revenues increased 8.4 percent year-over-year to $266.6 million in the quarter, from $246 million in the comparable quarter of 2003.
Net income for the quarter decreased to $22 million, or $.86 per share, from $26.4 million, or $1.04 per share in the year-ago period.
R&D expenses rose to $25.2 million, from $21.4 million a year ago.
As of March 31, 2004, Bio-Rad had $141.5 million in cash and cash equivalents.
GeneBio Opens Branch in Tokyo
Geneva Bioinformatics announced this week that it has opened a branch in Tokyo.
The company’s new Japanese branch will promote GeneBio’s proteomics and bioinformatics products and will help “build closer long-term relationships with Japanese customers and partners,” according to Nasri Nahas, GeneBio’s CEO.
Bruker and VWR Sign Co-Marketing Agreement for Europe
Bruker Daltonik announced this week that it has signed an agreement with VWR International’s Scientific Instruments business unit to co-market some of VWR’s HPLC products and Bruker Daltonik’s bench-top mass spectrometers in Europe.
VWR International will market Bruker Daltonik’s esquire4000 LC-MS/MS ion trap mass spectrometer in Europe along with its LaChrom Elite HPLC system, while Bruker Daltonik will offer the LaChrom Elite with its bench-top LC-MS ion trap and TOF systems.
Jingmei Biotech to Distribute ProteinOne’s Products in China
ProteinOne of College Park, Md. and Jingmei Biotech of Shenzhen, China announced last week that Jingmei will distribute ProteinOne’s products in China.
Under the terms of the agreement, Jingmei has a non-exclusive right to purchase, inventory, promote, and sell its recombinant proteins, protein kits, antibodies, Active Protein Array Platforms, and protein purification, production, and expression services in China.
Waters wins $17.4M in TA Suit from Applera
Waters announced this week that it has received $17.4 million in damages from Applera for a patent infringement suit concerning three patents for its thermal analysis technology.
The suit, originally filed against PerkinElmer in 1995, involved US patents 5,224,775; 5,346,306; and 5,439,291. A 2003 US District Court judgment found PerkinElmer liable for patent infringement of all three patents. On May 5, 2004, a US Court of Appeals affirmed the judgment.